4 active not recruiting, 4 recruiting, 3 terminated, 2 completed. 13 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 13 | Active not recruiting 4, Recruiting 3, Terminated 3, Completed 2, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Nader Sanai: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NST-628 in Recurrent Grade 4 Glioma NST-628 - Glioma, Recurrent High Grade, Grade 4 Malignant Glioma | Early Phase 1 | Not yet recruiting | Nader Sanai | 12 | 2026-10-01 | 2026-09-15 |
| BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors BGB-58067 - Glioblastoma (GBM) | Early Phase 1 | Recruiting | Nader Sanai | 78 | 2026-05-07 | 2026-08-21 |
| A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases Risvutatug rezetecan - Glioblastoma (GBM), Brain Metastasases | Early Phase 1 | Recruiting | Nader Sanai | 15 | 2026-02-11 | 2026-03-06 |
| Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas Quisinostat - Glioblastoma WHO Grade IV | Early Phase 1 | Active not recruiting | Nader Sanai | 30 | 2025-09-04 | 2026-03-17 |
| Clinical Trial of BMS-986504 in Recurrent GBM Patients BMS-986504 - Glioblastoma WHO Grade IV | Early Phase 1 | Recruiting | Nader Sanai | 12 | 2025-04-28 | 2026-06-25 |
| Abemaciclib in Newly Diagnosed Meningioma Patients Abemaciclib, Placebo - Meningioma | Phase 2 | Recruiting | Nader Sanai | 72 | 2025-03-24 | 2026-03-13 |
| Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG Temsirolimus - High Grade Glioma, Glioma | Early Phase 1 | Terminated | Nader Sanai | 5 | 2023-05-15 | 2026-05-14 |
| AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients AZD1390 - Glioblastoma, Glioma | Early Phase 1 | Active not recruiting | Nader Sanai | 97 | 2022-05-27 | 2026-03-09 |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Niraparib, Radiation therapy - Glioblastoma, Glioblastoma Multiforme | Early Phase 1 | Active not recruiting | Nader Sanai | 42 | 2021-10-29 | 2026-03-09 |
| Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS) - High Grade Glioma | Early Phase 1 | Terminated | Nader Sanai | 10 | 2021-03-15 | 2026-05-14 |
| Study of Pamiparib in Newly Diagnosed and rGBM Pamiparib, Olaparib, Radiation therapy - Glioblastoma, Glioblastoma Multiforme | Early Phase 1 | Completed | Nader Sanai | 50 | 2021-01-11 | 2026-05-14 |
| Infigratinib in Recurrent High-Grade Glioma Patients Infigratinib - Glioma, Glioblastoma | Early Phase 1 | Terminated | Nader Sanai | 7 | 2020-07-21 | 2025-10-24 |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients Abemaciclib, LY3214996 - Glioblastoma, GBM | Early Phase 1 | Completed | Nader Sanai | 42 | 2020-07-11 | 2026-03-06 |
| Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Ribociclib - Glioblastoma Multiforme, Meningioma | Early Phase 1 | Active not recruiting | Nader Sanai | 48 | 2016-10-17 | 2026-03-06 |
Glioblastoma (9) · Glioma (7) · Meningioma (2)
Radiotherapy (2) · abemaciclib (2) · AZD1390 (1) · LY3214996 (1) · Temozolomide (1) · infigratinib (1) · niraparib (1) · olaparib (1) · pamiparib (1) · quisinostat (1) · ribociclib (1) · temsirolimus (1)
United States (14)